IMMX immixbio.com: Enterprise Value to EBITDA Ratio

Graphic logo of Immix Biopharma (IMMX)

Immix Biopharma, Inc. (IMMX) focuses on the rapid expansion of clinical trials to combat tumors and autoimmune pathologies, leveraging alliances with oncology centers and the acquisition of innovative startups. This price action, featuring an EV/EBITDA metric of 0.00, complements the analysis of the business developing NXC-201 CAR-T therapy, which demonstrates success in treating myeloma and possesses potential for outpatient use.

Immix Biopharma Inc. - IMMX Total Company Value to Operating Income Before Depreciation Ratio (period 11/23/2025 - 11/12/2026)

Summary analytical data breakdowns for immixbio.com (IMMX)

- stock price and consensus target price:
Stock Quotes Immix Biopharma|IMMX - Average Forecast Price
- company stock capitalization data:
Market Valuation Immix Biopharma, Inc.|IMMX - Value Adjusted for Debt and Cash
- business book valuation details:
Book Value per Share Immix Biopharma|IMMX - Book Valuation of Business|Market Value to Book Value Ratio immixbio.com|IMMX - Cumulative Company Assets
- debt and solvency information:
Debt to Equity Immix Biopharma, Inc.|IMMX - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Ratio Immix Biopharma|IMMX - Company Aggregate Debts|Debt to Book Capitalization Ratio Immix Biopharma, Inc.|IMMX - Company Long-Term Indebtedness|Company Short-Term Debt Immix Biopharma|Quick Liquidity Indicator immixbio.com
- financial results and valuation multiples details:
IMMX - Annual Net Income|Future Profit Immix Biopharma, Inc.|IMMX - Market Price to Net Income Ratio|Forward P/E Multiple Immix Biopharma|IMMX - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Immix Biopharma, Inc.|IMMX - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Immix Biopharma|IMMX - Earnings per share for the trailing year|Quarterly EPS earnings growth immixbio.com|IMMX - Earnings growth in current year|Net earnings per share growth forecast for next year Immix Biopharma, Inc.
Fundamental company analysis:IMMX (Immix)
Original product of Immix Biopharma Inc.

The diversified immunotherapy pipeline of Immix Biopharma, Inc. (IMMX) allows the company to mitigate development risks, which is reflected in the fluctuations of the EV/EBITDA multiple over time. This ratio correlates the total enterprise value (market capitalization plus net debt) with operating profit before depreciation and amortization, enabling investors to determine the fair value of the asset regardless of debt load or tax regime to identify optimal entry points.

Competitor analysis for Immix Biopharma, Inc.

ImmunityBio Corp - Enterprise Value to EBITDA Ratio|Immunocore Corp (IMCR) - Company Value to EBITDA|JANX: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation RCUS (arcusbio.com)|ZYME: EV/EBITDA Multiple|TNGX - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Iovance|Enterprise Value to EBITDA Ratio Immatics Biotechnologies (IMTX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Xencor, Inc. (XNCR)|Enterprise Value to EBITDA Ratio compasstherapeutics.com CMPX|Replimune - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Lyell LYEL|IPHA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PYXS (Pyxis Oncology, Inc.) - Enterprise Value to Operating Income Before Depreciation|cgen.com (CGEN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA iobiotech.com (IOBT)|Enterprise Value to EBITDA Ratio STRO|INKT - Enterprise Value to EBITDA Multiple|Enterprise Value to EBITDA Ratio HOWL (Werewolf Therapeutics)|Enterprise Value to Operating Income Before Depreciation Ratio ALXO|EV/EBITDA Multiple CUE (Cue Biopharma)|Business Value to Operating Income Before Depreciation PDSB|Sonnet BioTherapeutics Holdings Inc. - EV/EBITDA Multiple|Company Value to EBITDA MAIA Biotech|Liminatus Pharma Corp (LIMN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|LAVA Therapeutics - Business Value to Operating Income Before Depreciation|NXTC (NextCure, Inc.) - EV/EBITDA Multiple|EV/EBITDA Multiple Leap Tx|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Intensity Therapeutics (INTS)|SNSE: Company Value to Operating Income Before Depreciation Ratio|Synthetic Biologics - Enterprise Value to EBITDA Ratio|Gritstone bio Inc. (GRTS) - Company Value to EBITDA|Kineta, Inc. - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio neximmune.com NEXI|turnstonebio.com (TSBX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Vaccinex Inc.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Harpoon Tx